Tempest Therapeutics revenue TPST

Sales by quarter and over the last twelve months, from 2014.

Tempest Therapeutics' revenue was $294K over the twelve months to Sep 30, 2018, down 9% on a year earlier.

In its latest quarter, Q3 FY18, it was $55K, down 2% on the same quarter a year before.

Revenue over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	Revenue	On a year earlier	Last 12 months
Q3 FY18	Sep 30, 2018	$55K	−2%	$294K
Q2 FY18	Jun 30, 2018	$81K	−4%	$295K
Q1 FY18	Mar 31, 2018	$67K	+6%	$298K
Q4 FY17	Dec 31, 2017	$91K	−25%	$294K
Q3 FY17	Sep 30, 2017	$56K	−72%	$324K
Q2 FY17	Jun 30, 2017	$84K	−56%	$465K
Q1 FY17	Mar 31, 2017	$63K	−57%	$570K
Q4 FY16	Dec 31, 2016	$121K	−23%	$653K
Q3 FY16	Sep 30, 2016	$197K	+163%	$689K
Q2 FY16	Jun 30, 2016	$189K	+530%	$567K
Q1 FY16	Mar 31, 2016	$146K	+873%	$408K
Q4 FY15	Dec 31, 2015	$157K	n/a	$277K

Companies in Drug Manufacturers - General nearest Tempest Therapeutics' size, closest first, today.

Company	Revenue, 12 months	Growth
TPSTTempest Therapeutics	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	$47M	−3% a year
LFVNLifevantage	$182.6M	−20% a year
Peer median	$114.8M

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.